^
    1d
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    1d
    Spark2: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • BMS-986253
    1d
    A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer. (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Chiayi Christian Hospital
    New trial
    1d
    Targeted Apoptosis Induction in Oral Squamous Cell Carcinoma by Goniothalamus umbrosus: A Pathway Through Bax, Bcl-2, and Caspase 3. (PubMed, Eur J Dent)
    The expression of Bax and Bcl-2 genes and caspase-3 protein activity was not significantly modulated in GUHE-treated HGF.GUHE selectively induced apoptosis by activating the mitochondrial apoptosis pathway in the HSC-3 cell line without being detrimental to the HGF cell line. This highlights its promising effect as a targeted therapeutic agent for OSCC therapy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    1d
    Multi-omics profiling of ACOX3 unveils pan-cancer clinical biomarker potential. (PubMed, Comput Biol Chem)
    ACOX3 represents a dual diagnostic and prognostic biomarker with broad pan-cancer relevance, exhibiting distinct immune correlates and therapeutic potential.
    Journal • Pan tumor
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    AZD6482 • TGX-221
    1d
    Generation and characterization of early stage oral cancer cell line of buccal mucosa of Indian origin. (PubMed, Hum Cell)
    RNA sequencing demonstrated upregulation of oral cancer-associated genes and pathways. Thus, in current study, we have reported development of novel cell line from early-stage buccal mucosa cancer patient which has a strong potential to be developed and to be used as pre-clinical model for improving oral cancer management and therapeutics.
    Preclinical • Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    1d
    Salivary cystatin D is a candidate non-invasive biomarker for primary Sjögren's syndrome diagnosis and salivary gland injury. (PubMed, Clin Exp Rheumatol)
    Salivary cystatin D emerged as a promising biomarker for pSS diagnosis and was correlated with salivary gland dysfunction.
    Journal
    |
    IL6 (Interleukin 6) • CD4 (CD4 Molecule)
    2d
    Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=44, Completed, Bristol-Myers Squibb | Terminated --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Erbitux (cetuximab)
    2d
    Carvacrol as a Promising Topical Agent against DMBA-Induced Oral Cancer in Rats: In vivo Study. (PubMed, Pak J Biol Sci)
    The group receiving carvacrol alternately with DMBA showed the most noticeable suppression in both markers. <b></b> These results highlight carvacrol's dual character in quashing carcinogenesis and stimulating apoptotic cell death, supporting its potential as a safe, natural therapeutic agent for OSCC intervention.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PCNA (Proliferating cell nuclear antigen)
    2d
    Genomic landscape of a long-term surviving patient with metastatic cancer of the larynx: a case report. (PubMed, Front Oncol)
    Our findings suggest that subtle regulatory variants may contribute to favorable clinical outcomes in rare long-term survivors of R/M HNSCC. Further studies are needed to identify predictive biomarkers in this unique subgroup of patients.
    Journal
    |
    EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • CTBP2 (C-Terminal Binding Protein 2)
    2d
    Endogenous Osteocyte-Osteoclast Signaling Enables Growth Factor-Free Bone Remodeling, Drug Response, and Cancer Invasion in a Nanoscale Calcified Bone-on-a-Chip Model. (PubMed, bioRxiv)
    Osteocyte-dependent osteoclastogenesis on-a-chip outperformed conventional stimulation with RANKL and M-CSF, reproduced the clinical response of anti-resorptive drugs, and mimicked established tumor-bone interactions observed in invasive oral cancer. By replicating essential aspects of bone composition and function, this system provides a robust, self-regulated microphysiologic model to investigate bone remodeling, cancer-bone crosstalk, and therapeutic interventions.
    Journal
    |
    CSF1 (Colony stimulating factor 1)
    2d
    cGAS-STING pathway reprograms macrophage polarization and is highly expressed in responding tumors after neoadjuvant immunotherapy in head and neck carcinoma. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    In support of translational relevance, analysis of single-cell RNA-seq data from HNSCC patients receiving neoadjuvant immunotherapy indicates that TMEM173 is expressed primarily in T cells and macrophages and that the cGAS-STING pathway score is significantly higher in patients who respond to treatment. Collectively, these findings provide systematic clinical and experimental evidence supporting the potential of STING agonists, such as MSA-2, to enhance antitumor immunity in HNSCC, particularly when combined with immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD68 (CD68 Molecule) • IFNA1 (Interferon Alpha 1) • CD80 (CD80 Molecule) • IFNB1 (Interferon Beta 1)